Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Clonal hematopoiesis in elderly twins: concordance, discordance and mortality

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Skin colonization by circulating neoplastic clones in cutaneous T-cell lymphoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Low vs. high hemoglobin trigger for Transfusion in Vascular surgery (TV): a randomized clinical feasibility trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Biological optimization for mediastinal lymphoma radiotherapy - a preliminary study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Deep learning for identification of critical regions associated with toxicities after liver stereotactic body radiation therapy

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Joachim Yahalom
  • Bouthaina Shbib Dabaja
  • Umberto Ricardi
  • Andrea Ng
  • N George Mikhaeel
  • Ivan R Vogelius
  • Tim Illidge
  • Shunan Qi
  • Andrew Wirth
  • Lena Specht
View graph of relations

The International Lymphoma Radiation Oncology Group (ILROG) guidelines for using radiation therapy (RT) in hematological malignancies are widely used in many countries. The emergency situation created by the COVID-19 pandemic may result in limitations of treatment resources. Furthermore, in recognition of the need to also reduce the exposure of patients and staff to potential infection with COVID-19, the ILROG task force has made recommendations for alternative radiation treatment schemes. The emphasis is on maintaining clinical efficacy and safety by increasing the dose per fraction while reducing the number of daily treatments. The guidance is informed by adhering to acceptable radiobiological parameters and clinical tolerability. The options for delaying or omitting RT in some hematological categories are also discussed.

Original languageEnglish
JournalBlood
Volume135
Issue number21
Pages (from-to)1829-1832
Number of pages4
ISSN0006-4971
DOIs
Publication statusPublished - 21 May 2020

    Research areas

  • Betacoronavirus/isolation & purification, Coronavirus Infections/epidemiology, Hematologic Neoplasms/radiotherapy, Humans, Lymphoma/radiotherapy, Pandemics/prevention & control, Pneumonia, Viral/epidemiology, Radiotherapy Dosage, Radiotherapy Planning, Computer-Assisted, Risk Factors, Time Factors

ID: 60922057